Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1645 1646 1674
This examiner grants 62% of resolved cases
Meera Natarajan is an examiner in Tech Center 1600 and Art Unit 1643, with 763 resolved cases. The allowance rate is 62.5 percent. The median time to allowance is 1177 days. These figures indicate a moderate level of difficulty and a standard prosecution timeline. The 763 resolved cases offer a stable data set for predicting future outcomes and understanding the examiner's typical pace for granting patents in this art unit.
The interview lift is 18.0 percent. This positive lift suggests that interviews are a helpful tactic for improving the odds of an allowance. Practitioners should use the 18.0 percent lift to justify an interview, particularly when facing rejections. The 1177-day median to allowance is a benchmark for managing client expectations. With a 62.5 percent allowance rate and an 18.0 percent lift, the examiner appears to be open to resolving issues through direct communication, making interviews a valuable tool for practitioners in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18528157 | ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOF | Non-Final OA | Janssen Biotech, Inc. |
| 17621303 | IN SITU RECRUITMENT, REPROGRAMMING, AND RELEASE OF CAR-T CELLS | Non-Final OA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL |
| 18639592 | COMPOSITIONS AND METHODS FOR MODULATING HYDROXYLATION OF ACC2 BY PHD3 | Non-Final OA | President and Fellows of Harvard College |
| 17969033 | METHODS FOR TREATING PRURIGO NODULARIS BY ADMINISTERING AN IL-4R ANTAGONIST | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18338313 | NOVEL METHOD FOR PRODUCING ANTIBODIES | Non-Final OA | TSINGHUA UNIVERSITY |
| 18558882 | DOUBLE SIDED CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED CELL MEMBRANE BASED DRUG DELIVERY SYSTEMS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18305292 | COILED COIL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF | Non-Final OA | THE SCRIPPS RESEARCH INSTITUTE |
| 18627727 | COMBINED ADMINISTRATION | Non-Final OA | Hoffmann-La Roche Inc. |
| 18699059 | ANTI-CD3 MONOCLONAL ANTIBODIES AND THERAPEUTIC CONSTRUCTS | Non-Final OA | UNIVERSITY OF OTTAWA |
| 18430415 | BISPECIFIC ANTIBODY CONSTRUCTS FOR CDH3 AND CD3 | Non-Final OA | AMGEN RESEARCH (MUNICH) GMBH |
| 17924695 | CHIMAERIC PROTEINS AND THERAPEUTIC AGENTS | Non-Final OA | Oxford University Innovation Limited |
| 18697515 | Combination Therapies for Treating Cancer | Non-Final OA | GlaxoSmithKline Intellectual Property Development Limited |
| 18690886 | USE OF ANTI-CD40 ANTIBODY | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18290668 | NOVEL CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELLS EXPRESSING SAME | Non-Final OA | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 17474389 | Checkpoint Inhibitor and Vaccine Combinations and Use of Same for Immunotherapy | Final Rejection | INOVIO PHARMACEUTICALS, INC. |
| 18634868 | ANTI-CD28 X ANTI-ENPP3 ANTIBODIES | Non-Final OA | Xencor, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy